TheranosticTrials.org

Clinical Trial · NCT06602037

ImmunoPET Imaging of Pancreatic Cancer

Overview

Pancreatic cancer remains one of the most aggressive cancer types. Target-specific targeted therapy is an attractive therapeutic alternative for the treatment of patients with a wide range of cancers, including pancreatic cancer. Companion diagnostic technique is critical for the success of targeted therapies. SHR-A1921 is a TROP2-directed antibody-drug-conjugate (ADC) approved for several clinical trials for advanced solid tumors. SHR1920 is the humanized anti-Trop2 monoclonal antibody (hIgG1) of SHR-A1921. Radio-labeling SHR1920 with radionuclide Zirconium-89 (89Zr) enables non-invasive imaging and quantification of SHR-A1921 distribution in cancer patients. Performing a \[89Zr\]Zr-DFO-SHR1920 PET scan before treatment with SHR-A1921 can evaluate tracer uptake in the primary and metastatic tumor lesions and normal organ distribution. CLND18.2 is another potential therapeutic target for pancreatic cancer. Target-specific immunoPET imaging may help identify patients more likely to benefit from targeted therapy.

Sponsor

RenJi Hospital

Phase

N/A

Contacts

Shuxian An, Ph.D. & M.D. (CONTACT)

anshuxian@shsmu.edu.cn

17717453484

Weijun Wei, Ph.D. & M.D. (CONTACT)

wwei@shsmu.edu.cn

15000083153

Jianjun Liu, PhD (STUDY_CHAIR)

Weijun Wei, Ph.D. & M.D. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06602037

Drug / Compound

3A12

Isotope(s):
Target(s):
  • Claudin 18.2
Ligand Class: Small Proteins and Antibody Fragments
Chelator: RESCA

3A12

Isotope(s):
Target(s):
  • Claudin 18.2
Ligand Class: Small Proteins and Antibody Fragments
Chelator: NOTA

SHR1920

Isotope(s):
Target(s):
  • Trop-2
Ligand Class: Antibodies
Chelator: DFO

Eligibility

Inclusion

  • Histologically confirmed diagnosis of pancreatic cancer or suspected pancreatic cancer by diagnostic imaging.

Exclusion

  • Known or suspected hypersensitivity to SHR1920, DFO/RESCA/NOTA, 89Zr/18F or 68Ga or any of the excipients.
  • Pregnancy